These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29285874)

  • 1. Early cellular interactions and immune transcriptome profiles in human factor VIII-exposed hemophilia A mice.
    Lai JD; Cartier D; Hartholt RB; Swystun LL; van Velzen AS; den Haan JMM; Hough C; Voorberg J; Lillicrap D
    J Thromb Haemost; 2018 Mar; 16(3):533-545. PubMed ID: 29285874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
    Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
    J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.
    Zerra PE; Cox C; Baldwin WH; Patel SR; Arthur CM; Lollar P; Meeks SL; Stowell SR
    Blood; 2017 Dec; 130(23):2559-2568. PubMed ID: 28978569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner.
    Swystun LL; Notley C; Georgescu I; Lai JD; Nesbitt K; James PD; Lillicrap D
    J Thromb Haemost; 2019 Apr; 17(4):681-694. PubMed ID: 30740857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A.
    Navarrete A; Dasgupta S; Delignat S; Caligiuri G; Christophe OD; Bayry J; Nicoletti A; Kaveri SV; Lacroix-Desmazes S
    J Thromb Haemost; 2009 Nov; 7(11):1816-23. PubMed ID: 19682235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain.
    Herczenik E; van Haren SD; Wroblewska A; Kaijen P; van den Biggelaar M; Meijer AB; Martinez-Pomares L; ten Brinke A; Voorberg J
    J Allergy Clin Immunol; 2012 Feb; 129(2):501-9, 509.e1-5. PubMed ID: 21962992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
    Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
    J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells.
    Hartholt RB; Wroblewska A; Herczenik E; Peyron I; Ten Brinke A; Rispens T; Nolte MA; Slot E; Claassens JW; Nimmerjahn F; Verbeek JS; Voorberg J
    J Thromb Haemost; 2017 Feb; 15(2):329-340. PubMed ID: 27868337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
    Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The humoral response to human factor VIII in hemophilia A mice.
    Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P
    J Thromb Haemost; 2007 Mar; 5(3):512-9. PubMed ID: 17181826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
    Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Removal of Mannose-Ending Glycan at Asn
    Delignat S; Rayes J; Dasgupta S; Gangadharan B; Denis CV; Christophe OD; Bayry J; Kaveri SV; Lacroix-Desmazes S
    Front Immunol; 2020; 11():393. PubMed ID: 32273875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
    Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
    J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
    Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
    J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.
    Qadura M; Waters B; Burnett E; Chegeni R; Bradshaw S; Hough C; Othman M; Lillicrap D
    Blood; 2009 Jul; 114(4):871-80. PubMed ID: 19411636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
    Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
    J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
    Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
    Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
    Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
    J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
    Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
    J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model.
    Sun J; Yuan Z; Abajas YL; Szollosi DE; Hu G; Hua B; Xiao X; Li C
    Hum Gene Ther; 2018 Mar; 29(3):381-389. PubMed ID: 28922951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.